Indication
Metastatic colorectal cancer with BRAF V600E mutation
Metastatic colorectal cancer with BRAF V600E mutation is an advanced gastrointestinal malignancy in which primary epithelial tumors of the colon or rectum have spread to distant anatomical sites, such as the liver, peritoneum, distant lymph nodes, or lungs. Read more about Metastatic colorectal cancer with BRAF V600E mutation
4 drugs 4 manufacturers
Drugs that treat it
Common Metastatic colorectal cancer with BRAF V600E mutation therapies.
ERBITUX (cetuximab)
BRAFTOVI (encorafenib)
BRAFTOVI (encorafenib)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonMetastatic colorectal cancer with BRAF V600E mutation is an advanced gastrointestinal malignancy in which primary epithelial tumors of the colon or rectum have spread to distant anatomical sites, such as the liver, peritoneum, distant lymph nodes, or lungs.
This clinically distinct molecular subtype, occurring in approximately 8% to 12% of metastatic colorectal cancer cases, is defined by an activating valine-to-glutamic acid substitution at codon 600 of the BRAF kinase.
This alteration constitutively drives downstream MAPK/ERK pathway signaling independent of upstream epidermal growth factor receptor activation.
Clinically and pathologically, tumors harboring this mutation frequently originate in the right colon, show mucinous or poorly differentiated histology, demonstrate frequent peritoneal dissemination, and exhibit an aggressive clinical course characterized by reduced sensitivity to standard chemotherapy and poor overall survival.
- nih.gov
Metastatic colorectal cancer with BRAF V600E mutation is an advanced gastrointestinal malignancy in which primary epithelial tumors of the colon or rectum have spread to distant anatomical sites, such as the liver, peritoneum, distant lymph nodes, or lungs This clinically distinct molecular subtype, occurring in approximately 8% to 12% of metastatic colorectal cancer cases, is defined by an activating valine-to-glutamic acid substitution at codon 600 of the BRAF kinase This alteration constituti...
- nih.gov
Metastatic colorectal cancer with BRAF V600E mutation is an advanced gastrointestinal malignancy in which primary epithelial tumors of the colon or rectum have spread to distant anatomical sites, such as the liver, peritoneum, distant lymph nodes, or lungs Clinically and pathologically, tumors harboring this mutation frequently originate in the right colon, show mucinous or poorly differentiated histology, demonstrate frequent peritoneal dissemination, and exhibit an aggressive clinical course c...
- mypathologyreport.ca
This clinically distinct molecular subtype, occurring in approximately 8% to 12% of metastatic colorectal cancer cases, is defined by an activating valine-to-glutamic acid substitution at codon 600 of the BRAF kinase This alteration constitutively drives downstream MAPK/ERK pathway signaling independent of upstream epidermal growth factor receptor activation
- amegroups.org
This clinically distinct molecular subtype, occurring in approximately 8% to 12% of metastatic colorectal cancer cases, is defined by an activating valine-to-glutamic acid substitution at codon 600 of the BRAF kinase Clinically and pathologically, tumors harboring this mutation frequently originate in the right colon, show mucinous or poorly differentiated histology, demonstrate frequent peritoneal dissemination, and exhibit an aggressive clinical course characterized by reduced sensitivity to s...
Personalize your experience
Follow Metastatic colorectal cancer with BRAF V600E mutation and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.